Introduction-Reference-Cited by-同舟云学术

Introduction

Published:2019-08 Issue:8 Volume:46 Page:962-968
ISSN:0315-162X
Container-title:The Journal of Rheumatology
language:en
Short-container-title:J Rheumatol

Author:

MARCH LYN^ORCID,RICHARDS BETHAN^ORCID,GILL MICHAEL,BROOKS PETER M.^ORCID,SHEA BEVERLEY J.^ORCID,BEATON DORCAS E.^ORCID,MAXWELL LARA J.^ORCID,TUNIS SEAN R.^ORCID,GROSSKLEG SHAWNA^ORCID,TUGWELL PETER^ORCID

Publisher

The Journal of Rheumatology

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference40 articles.

1. The OMERACT filter for outcome measures in rheumatology;Boers;J Rheumatol,1998

2. Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0

3. OMERACT Patient Research Partner Network . [Internet. Accessed January 4, 2019.] Available from: https://omeractprpnetwork.org/

4. Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials

5. Cheah J Black R Robson J Navarro-Millan I Young S Richards P Toward a core domain set for glucocorticoid impact in inflammatory rheumatic diseases: the OMERACT 2018 glucocorticoid impact working group. J Rheumatol 2019 (in press).

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fostering connections at OMERACT 2023: A collaborative approach to Core Outcome Set development;Seminars in Arthritis and Rheumatism;2024-08

2. Increasing uptake through collaboration in the development of core outcome sets: Lessons learned at OMERACT 2023;Seminars in Arthritis and Rheumatism;2024-06

3. Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France;Value in Health;2020-04